Effect of dapagliflozin, the sodium-glucose-cotransporter-2 (SGLT2) inhibitor, on fibroblast growth factor 21 (FGF21), a novel hepatokine and myokine, in Japanese patients of type 2 diabetes - Effect of dapagliflozin on FGF21.

ational Hospital Organization Kyoto Medical Center0 个研究点目标入组 60 人开始时间: 2016年4月1日最近更新: 2023年10月17日

适应症

试验速览

阶段: 4 期
状态: 已完成
发起方
入组人数: 60

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

Bodyweight decreased in the dapagliflozin group, but the changes in SMM were not significant between the groups, thereby elevating the ratio of SMM-to-bodyweight in the dapagliflozin group. Myostatin levels were significantly decreased, and irisin levels showed a nearly significant reduction in the dapagliflozin group compared with the control group, whereas FGF21 levels did not change significantly from baseline to the end of the intervention in both groups.

研究设计

研究类型: Interventional

入排标准

年龄范围: 20years-old 至 80years-old（—）
性别: All

入选标准

未提供

排除标准

•1.Subjects with secondary obesity associated with endocrine disorders 2.Type 1 diabetes mellitus 3.Subjects with severe ketosis, diabetic coma or precoma 4.Subjects with severe infection, before and after surgery or severe injury 5.Subjects with severe hepatic dysfunction 6.Subjects with moderate or more of renal dysfunction (serum creatinine >= 1.5mg/dl[male], 1.3mg/dl[female]). 7.The subjects within the past 6 months, developed stroke, myocardial infarction, or other serious vascular complications requiring hospitalization 8.Subjects with dehydration, diarrhea, vomiting or gastrointestinal injury 9.Subjects in SGLT-2 inhibitors, insulin formulation, GLP-1 receptor agonist prescription 10.Subjects in TZD, fibrate prescription 11.Subjects in pregnant women, lactating women, the potential or planned are pregnant 12.Subjects with a history of hypersensitivity to SGLT-2 inhibitor 13.Subjects who have been determined to be unsuitable for the attending physician

研究者

发起方

ational Hospital Organization Kyoto Medical Center

相似试验

已完成

4 期

Phase IV study of switching from sitagliptin to ipragliflozin in obese patients with type 2 diabetesDiabetes mellitus

JPRN-jRCTs031190022Ishihara Hisamitsu51

已完成

不适用

Effects of Dapagliflozin on Body Weight in Japanese Patients with Type 2 Diabetes Mellitus. SUMS-ADDIT-2Type 2 diabetes

JPRN-UMIN000020239Shiga University of Medical Science52

尚未招募

4 期

Comparative effects of dapagliflozin and metformin in obese diabetic patients

CTRI/2023/11/059814Shobana

已完成

Unknown

Study on the glucose-lowering effect and metabolic benefit of SGLT2 inhibitorsDiabetes mellitus

JPRN-UMIN000052955Department of Internal Medicine, Kurume University School of Medicine17

进行中（未招募）

1 期

Effects of glucose-lowering interventions in pre-diabetes

EUCTR2015-001552-30-DKSteno Diabetes Center A/S160